Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick A Ott

Showing results (11-20 of 179) with videos related to

Pageof 18
Sort By:
Cancer Cell|May 11, 2026
Bridging clinical gaps in personalized cancer neoantigen vaccinesKaram Khaddour, Patrick A Ott
Drug, Healthcare and Patient Safety|July 15, 2014
New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapyJason J Luke, Patrick A Ott
Oncotarget|January 2, 2018
PD-1 inhibitors in endometrial cancerRomualdo Barroso-Sousa, Patrick A Ott
Chinese Clinical Oncology|April 6, 2015
The B7-H1/PD-1 pathway in cancers associated with infections and inflammation: opportunities for therapeutic interventionPatrick A Ott, F Stephen Hodi
Oncotarget|February 17, 2015
PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanomaJason J Luke, Patrick A Ott
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2017
Reply to F. Tomao et alPatrick A Ott, Jean-Charles Soria
Cancer Discovery|March 14, 2019
Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate TumorsPatrick A Ott, Catherine J Wu
Cancer Metastasis Reviews|March 23, 2017
Erratum to: Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanomaDavid J Hermel, Patrick A Ott
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2016
Talimogene Laherparepvec for the Treatment of Advanced MelanomaPatrick A Ott, F Stephen Hodi
Current Oncology Reports|December 1, 2018
Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 InhibitorsRomualdo Barroso-Sousa, Patrick A Ott
Pageof 18

Showing results (11-20 of 179) with videos related to

Sort By:
Pageof 18
Cancer Cell|May 11, 2026
Bridging clinical gaps in personalized cancer neoantigen vaccinesKaram Khaddour, Patrick A Ott
Drug, Healthcare and Patient Safety|July 15, 2014
New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapyJason J Luke, Patrick A Ott
Oncotarget|January 2, 2018
PD-1 inhibitors in endometrial cancerRomualdo Barroso-Sousa, Patrick A Ott
Chinese Clinical Oncology|April 6, 2015
The B7-H1/PD-1 pathway in cancers associated with infections and inflammation: opportunities for therapeutic interventionPatrick A Ott, F Stephen Hodi
Oncotarget|February 17, 2015
PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanomaJason J Luke, Patrick A Ott
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 8, 2017
Reply to F. Tomao et alPatrick A Ott, Jean-Charles Soria
Cancer Discovery|March 14, 2019
Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate TumorsPatrick A Ott, Catherine J Wu
Cancer Metastasis Reviews|March 23, 2017
Erratum to: Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanomaDavid J Hermel, Patrick A Ott
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2016
Talimogene Laherparepvec for the Treatment of Advanced MelanomaPatrick A Ott, F Stephen Hodi
Current Oncology Reports|December 1, 2018
Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 InhibitorsRomualdo Barroso-Sousa, Patrick A Ott
Pageof 18